SCHEMBL2858192

SCHEMBL2858192

CC(C)(C)OC(=O)N1CCN2C(=O)OCC2(Cc2ccccc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.42
SCD5 Q86SK9 1/20 0.41
DTYMK P23919 1/20 0.41
GPR119 Q8TDV5 3/20 0.40
STS P08842 1/20 0.40
USP30 Q70CQ3 2/20 0.40
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
ACKR3 P25106 1/20 0.38
CYP11B2 P19099 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13176131 0.84 FKBP1A (0.35) GAASMN1; SMN2
SCHEMBL5231428 0.82 STS (0.44) ACHEDTYMKGPR119STSUSP30
SCHEMBL5231431 0.82 STS (0.44) ACHEDTYMKGPR119STSUSP30
SCHEMBL5230321 0.82 ACHE (0.42) ACHESCD5DTYMKGPR119STS
SCHEMBL5232478 0.82 GPR119 (0.43) ACHEDTYMKGPR119STSUSP30
SCHEMBL5232846 0.81 ACHE (0.44) ACHEDTYMKGPR119STSUSP30
SCHEMBL6835127 0.77 STS (0.36) ACHESCD5GPR119STSOPRD1
SCHEMBL13452646 0.75 SMN1; SMN2 (0.47) ACHESCD5GPR119STSUSP30
SCHEMBL5224573 0.75 GHSR (0.60)
SCHEMBL6699145 0.74 ACHE (0.42) ACHEDTYMKGPR119STSUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US disclosed
US-20020065284-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-05-30 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR ACHE 3514/4885SCD5 3980/4885DTYMK 4740/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885SCD5 4152/4885DTYMK 4002/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 4103/4885SCD5 4128/4885DTYMK 3411/4885
US-20020002165-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885SCD5 4152/4885DTYMK 4002/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3741/4885SCD5 3877/4885DTYMK 3758/4885
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 ACHE 4725/4885SCD5 896/4885DTYMK 4147/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885SCD5 4152/4885DTYMK 4002/4885
US-20020065284-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885SCD5 4152/4885DTYMK 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.